ʻIke kumu
inoa mea kūʻai | Heluhelu | ʻAno | Mea hoʻokipa/kumu | Hoʻohana | Nā noi | COA |
HCV Core-NS3-NS5 fusion antigen | BMGHCV101 | Antigen | ʻEkoli | Hopu | LF, IFA, IB, WB | Hoʻoiho |
HCV Core-NS3-NS5 fusion antigen | BMGHCV102 | Antigen | ʻEkoli | Hoʻohui | LF, IFA, IB, WB | Hoʻoiho |
ʻO ka hapa nui o nā maʻi ʻaʻohe hōʻailona ʻike ʻia i ka pae koʻikoʻi o ka maʻi, hele pū me nā pae kiʻekiʻe o ka viremia a me ka piʻi ʻana o ALT.Ua ʻike ʻia ka HCV RNA i ke koko ma mua o ka anti HCV ma hope o ka maʻi HCV koʻikoʻi.Hiki ke ʻike ʻia ka HCV RNA i 2 mau pule ma hope o ka hoʻolaha ʻana, hiki ke ʻike ʻia ka HCV core antigen 1 a 2 mau lā ma hope o ka puka ʻana o HCV RNA, a ʻaʻole hiki ke ʻike ʻia ka anti HCV a hiki i ka 8 a 12 mau pule, ʻo ia hoʻi, ma hope o ka maʻi HCV, aia ma kahi o 8-12 mau pule, ʻo HCV RNA wale nō ke ʻike ʻia, ʻo ka anti HCV ka lōʻihi, ʻo ka anti HCV ka lōʻihi, ʻo ka anti HCV ka lōʻihi. pili ka "window period" i ka reagent detection (e nānā i ka Papa 1).ʻAʻole he antibody pale ka Anti HCV, akā he hōʻailona o ka maʻi HCV.Hiki i ka 15%~40% o nā maʻi me ka maʻi HCV koʻikoʻi ke hoʻomaʻemaʻe i ka maʻi i loko o 6 mahina.I ka hoʻomaʻemaʻe ʻana i ka maʻi, haʻahaʻa loa ka pae HCV RNA i ʻike ʻole ʻia, a ʻo ka anti HCV wale nō ka maikaʻi;Eia naʻe, ʻaʻole i hoʻomaʻemaʻe ʻia ka 65% ~ 80% o nā maʻi no 6 mau mahina, i kapa ʻia ʻo ka maʻi HCV mau loa.Ke hiki mai ka ma'i hepa C ma'i, ho'omaka ka HCV RNA titer e ho'opa'a, a he kakaikahi ka ho'iho'i 'ana.Inā ʻaʻole i hoʻokō ʻia ka lāʻau antiviral maikaʻi, ʻaʻole hiki ke hoʻomaʻemaʻe wale ʻia ka HCV RNA.Ma ka hoʻomaʻamaʻa lapaʻau, ʻo ka hapa nui o nā maʻi me ka maʻi hepa C maʻi maʻi maikaʻi no ka anti HCV (nā maʻi immunosuppressed, e like me nā maʻi i loaʻa i ka maʻi HIV, nā mea hoʻololi o ke kino paʻa, nā mea maʻi me ka hypogammaglobulinemia a i ʻole nā mea maʻi hemodialysis he ʻino no ka anti HCV), a he maikaʻi a maikaʻi ʻole paha ka HCV RNA (he haʻahaʻa ka pae HCV RNA ma hope o ka mālama antiviral).